Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies (Details Textual)

v2.4.0.6
Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)
 1 Months Ended 3 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2005
May 31, 2012
Nov. 30, 2012
Deliverable
Segment
Agreement
License
Directors
Compensation_Plan
Nov. 30, 2011
Aug. 25, 2011
Nov. 30, 2012
Minimum [Member]
Nov. 30, 2012
Maximum [Member]
Nov. 30, 2012
CEO [Member]
Nov. 30, 2011
Variable Rate Demand Notes [Member]
Nov. 30, 2012
Exchange Traded Equity Securities [Member]
Nov. 30, 2011
Exchange Traded Equity Securities [Member]
Nov. 30, 2012
Credit Concentration Risk [Member]
Nov. 30, 2011
Credit Concentration Risk [Member]
Nov. 30, 2012
Saneron Therapeutics [Member]
Nov. 30, 2012
Saneron Therapeutics [Member]
CCEL Bio Therapies Inc [Member]
Oct. 10, 2001
Saneron Therapeutics [Member]
CCEL Bio Therapies Inc [Member]
Nov. 30, 2012
Saneron Therapeutics [Member]
Stem Cell Preservation Technologies Inc [Member]
Nov. 30, 2012
Saneron [Member]
Nov. 30, 2011
Saneron [Member]
Basis of Presentation and Significant Accounting Policies (Textual) [Abstract]                                      
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary                             260,000   195,000    
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary                           $ 3,900   $ 1,924,000      
Non-controlling interest after merger                                   43.42%  
Ownership interest                                   34.00% 34.00%
Condition for recording equity losses                                   0  
Impairment of investment                                   0  
Percentage of Accounts receivable and Advances due from certain foreign license affiliates                       55.00% 41.00%            
Contracted storage periods           1 year 21 years                        
Variable rate demand notes                 1,002,000 0 6,404                
Immediate vesting of the options included in stock compensation expense     1,325,196 329,001       700,000                      
Basis of Presentation and Significant Accounting Policies (Additional Textual) [Abstract]                                      
Number of reportable segment     1                                
Number of shares issued to subsidiary     0                                
Number of deliverables for revenue recognized     2                                
Restricted cash     2,576,844 2,700,000                              
Cash required to be deposited in bank for issuance of Letter of credit     200,000                                
Transfer of Funds to a Grantor Trust for payments under certain executive employment agreements         2,500,000                            
Period of doubtful for Accounts receivable Due from client     30 days                                
Impairment of Long-Lived Assets Held-for-use     0 627,034                              
Writing off abandoned patent and trademarks     52,536 210,171                              
Amortization expense     74,000 40,000                              
Less: Accumulated amortization     (87,249) (74,060)                              
Amortization Period     20 years                                
Less: Valuation Allowance     10,947,000 7,756,000                              
Stock option compensation expense     1,325,000 329,000                              
Reserves recorded under programs     14,485 13,351                              
U.S. Income tax expense   1,718,919   0                              
Number of outstanding options     1,823,098 608,419                              
Foreign income tax expense     169,000 172,000                              
Payment Warranty 50,000                                    
Additional payment warranty     10,000                                
Increased payment warranty     75,000                                
Minimum percentage probability of realized tax benefit on settlement     50.00%                                
Provisions for interest or penalties related to uncertain tax positions     0 0                              
Advertising cost included in marketing, general and administrative expenses     692,000 2,200,000                              
Exchange-traded equity securities     20,760 0                              
Variable rate demand notes reset period     7 days                                
Unrealized holding gain recorded in other income and expense     7,100                                
Gain or loss recognized on redemption     0                                
Concentration risk related to supplier     Company dependency on one supplier for the source of collection kits                                
Number of licensing agreement made by entity     14                                
Number of share based compensation plans     3                                
Number of individuals nominated for directors     6                                
Legal fees allocated to trust balance     81,250 0                              
Share based compensation accelerated cost     171,000                                
Impairment charges for long lived assets     $ 0                                
Number of license agreement     2